0K2H Stock Chart & Stats
$1.13
-$0.33(-29.20%)
At close: 4:00 PM EDT
$1.13
-$0.33(-29.20%)
Day’s Range― - ―
52-Week Range$0.24 - $18.50
Previous CloseN/A
Volume44.88K
Average Volume (3M)27.98K
Market Cap
$4.06M
Enterprise Value-$0.55
Total Cash (Recent Filing)$7.26M
Total Debt (Recent Filing)$147.00K
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,100,713
10 Day Avg. Volume14,289
30 Day Avg. Volume27,983
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.26
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside1758.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal MIRACLE Trial Efficacy SignalsInterim MIRACLE results showing materially higher complete and composite remission rates versus historical salvage benchmarks indicate a durable clinical signal. If sustained in full unblinded and pivotal analyses, this can validate Annamycin's therapeutic profile, support regulatory progress, and materially improve partnering and commercial prospects over months.
Differentiated Cardiac Safety ProfilePooled safety data demonstrating no cardiotoxicity versus conventional anthracyclines is a structural competitive advantage. It can expand eligible patient pools, enable higher cumulative dosing/bridging to transplant, and support a distinct label and payer value proposition—advantages that persist through commercialization if confirmed.
Strengthened Intellectual PropertyAddition of jurisdictional patents (Hong Kong plus existing US/EU/Asia grants) bolsters territorial exclusivity and creates a more defensible commercialization moat. Robust patent coverage supports licensing, partnership negotiations, and long-term market protection against generics across key oncology markets.
Bears Say
Zero Revenue And Sustained Cash BurnThe company remains pre-revenue with substantial and persistent operating losses and negative free cash flow. This structural cash burn forces repeated external financings to sustain trials, raises dilution risk, and constrains the firm's ability to self-fund late-stage development or early commercial launches without partners over the next several quarters.
Shrinking Equity And Asset BaseA materially declining equity and asset base reduces solvency cushions and financial flexibility. Over a multi-month horizon this amplifies fundraising urgency, weakens negotiating leverage with partners or licensors, and increases the chance that future financing will be done on dilutive or restrictive terms if clinical progress stalls.
Ongoing Reliance On Dilutive Financing And Warrant OverhangRecent equity financing improves near-term runway but embeds warrant overhang, anti-dilution clauses and ownership caps that compress future equity economics and restrict capital options. This structural dependence on equity raises long-term dilution risk and can limit the company's ability to pursue non-dilutive partnerships or flexible financing.
Moleculin Biotech News
0K2H FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest share price was $0.24 and its highest was $18.50 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $4.06M.
When is Moleculin Biotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Moleculin Biotech’s earnings last quarter?
Currently, no data Available
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 7,100,713 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in GB:0K2H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
0K2H Stock 12 Month Forecast
Average Price Target
$21.00
▲(1758.41% Upside)